UA99719C2 - Вакцина для собак против болезни лайма - Google Patents

Вакцина для собак против болезни лайма

Info

Publication number
UA99719C2
UA99719C2 UAA200905686A UAA200905686A UA99719C2 UA 99719 C2 UA99719 C2 UA 99719C2 UA A200905686 A UAA200905686 A UA A200905686A UA A200905686 A UAA200905686 A UA A200905686A UA 99719 C2 UA99719 C2 UA 99719C2
Authority
UA
Ukraine
Prior art keywords
lyme disease
disease vaccine
canine lyme
canine
vaccine
Prior art date
Application number
UAA200905686A
Other languages
English (en)
Ukrainian (uk)
Inventor
Стивен М. Каллистер
Ронда Лафльор
Терри Л. Васмеуэн
Original Assignee
Шеринг-Плау Лтд.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Шеринг-Плау Лтд. filed Critical Шеринг-Плау Лтд.
Publication of UA99719C2 publication Critical patent/UA99719C2/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/0225—Spirochetes, e.g. Treponema, Leptospira, Borrelia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pulmonology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)

Abstract

Изобретение касается вакцины для собак против болезни Лайма, которая содержит иммунологически эффективное количество организмов первого штамма геновидов боррелий и иммунологически эффективное количество организмов второго штамма геновидив боррелий, где организмы указанного второго штамма экспрессируют на свои поверхности Ospa антиген, Ospb антиген или экспрессируют оба Ospa и Ospb антигена, и где введение указанной вакцины собаке вызывает вырабатывание значительных уровней антител против В. burgdorferi ss 50772 (АТСС No. PTA-439).
UAA200905686A 2006-11-03 2007-11-01 Вакцина для собак против болезни лайма UA99719C2 (ru)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US86425806P 2006-11-03 2006-11-03

Publications (1)

Publication Number Publication Date
UA99719C2 true UA99719C2 (ru) 2012-09-25

Family

ID=39365056

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA200905686A UA99719C2 (ru) 2006-11-03 2007-11-01 Вакцина для собак против болезни лайма

Country Status (17)

Country Link
US (2) US8137678B2 (ru)
EP (1) EP2077856B1 (ru)
JP (3) JP5177824B2 (ru)
KR (1) KR101192127B1 (ru)
CN (1) CN101573135B (ru)
AU (1) AU2007318026B2 (ru)
BR (1) BRPI0719360B1 (ru)
CA (1) CA2668405C (ru)
CO (1) CO6190537A2 (ru)
IL (1) IL198485A0 (ru)
MX (1) MX2009004866A (ru)
NZ (1) NZ576564A (ru)
RU (1) RU2460538C2 (ru)
SG (1) SG176451A1 (ru)
UA (1) UA99719C2 (ru)
WO (1) WO2008057396A2 (ru)
ZA (1) ZA200903378B (ru)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0757556B1 (en) * 1994-04-11 2006-06-14 Wyeth Holdings Corporation Borrelia burgdorferi bacterin
MX2009004866A (es) * 2006-11-03 2009-05-19 Schering Plough Ltd Vacuna para enfermedad de lyme canina.
CZ301244B6 (cs) * 2007-11-14 2009-12-16 Bioveta, A.S. Univerzální vakcína k lécbe a prevenci Lymeské borreliózy pro humánní a veterinární použití a zpusob její výroby
US8313915B2 (en) * 2009-01-21 2012-11-20 Gundersen Lutheran Medical Foundation, Inc. Early detection of canine lyme disease by specific peptides and antibodies
BR112013009588A2 (pt) * 2010-10-20 2017-10-10 Univ Virginia Commonwealth vacinógeno ospc quimérico polivalente e antígeno para diagnóstico
US9050282B2 (en) * 2012-07-17 2015-06-09 Merial, Inc. Method of providing protective immunity against heterologous leptospira strains
US11883476B2 (en) 2017-12-04 2024-01-30 Intervet Inc. Canine lyme disease vaccine
CN111097044B (zh) * 2019-12-18 2026-03-20 北京华夏兴洋生物科技有限公司 犬型钩端螺旋体、黄疸出血型钩端螺旋体、犬冠状病毒三联灭活疫苗
BR112022011850A2 (pt) * 2019-12-18 2022-09-06 Intervet Int Bv Vacina respiratória oral
CN120796148B (zh) * 2025-09-03 2026-02-17 青岛农业大学 一株犬支原体、培养方法及其应用

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6054296A (en) 1988-10-24 2000-04-25 Symbicom Ab 66 kDa antigen from Borrelia
DK590288D0 (da) 1988-10-24 1988-10-24 Symbicom Ab Kemiske forbindelser
US4002736A (en) 1974-12-16 1977-01-11 Pankratz Duane C Porcine bacterin
US4721617A (en) 1986-08-14 1988-01-26 Regents Of The University Of Minnesota Vaccine against lyme disease
US4712617A (en) * 1986-10-03 1987-12-15 The Dow Chemical Company Method for controlling the flow of liquids through a subterranean formation
US5246844A (en) 1991-10-22 1993-09-21 Board Of Regents, The University Of Texas System Virulence associated proteins in borrelia burgdorferi (bb)
US6300101B1 (en) 1988-10-24 2001-10-09 Board Of Regents, The University Of Texas System Methods and compositions including a 13kD B. burgdorferi protein
US7094391B1 (en) 1988-10-24 2006-08-22 The University Of Texas System Compositions and methods for administering Borrelia burgdorferi antigens
US6143872A (en) 1988-10-24 2000-11-07 Symbicom Aktiebolag Borrelia burdorferi Osp A and B proteins and immunogenic peptides
US5777095A (en) 1988-10-24 1998-07-07 Symbicom Aktiebolag Osp A and B Sequence of Borrelia burgdonferi strains ACA1 and IP90
US5385826A (en) 1989-04-21 1995-01-31 Gundersen Medical Foundation, Ltd. Diagnostic assay for lyme disease
DE4015911A1 (de) 1989-09-19 1991-03-28 Max Planck Gesellschaft Impfstoff gegen die lyme-krankheit
US5582829A (en) 1990-04-05 1996-12-10 Rx Technologies, Inc. Sonicated borrelia burgdorferi vaccine
SG122738A1 (en) 1990-06-15 2006-06-29 Univ Yale Compositions and methods for the prevention and diagnosis of lyme disease
IE912303A1 (en) 1990-07-06 1992-01-15 American Home Prod Vaccine against lyme disease and a challenge model for¹evaluating vaccine efficiency
US5436000A (en) 1991-01-11 1995-07-25 University Of Texas System Flagella-less borrelia
US6872550B1 (en) 1991-07-11 2005-03-29 Baxter Vaccine Ag Immunogenic formulation of OspC antigen vaccines for the prevention and treatment of lyme disease and recombinant methods for the preparation of such antigens
US6221363B1 (en) 1991-07-11 2001-04-24 Baxter Aktiengesellschaft Vaccine for the prevention of lyme disease
US6113914A (en) 1991-08-15 2000-09-05 Smithkline Beecham Biologicals (S.A.) Osp A proteins of Borrelia burgdorferi subgroups, encoding genes and vaccines
ES2194010T3 (es) 1991-10-22 2003-11-16 Symbicom Ab Mejoras en el diagnostico y profilaxis de la borrelia burgdorferi.
WO1993024145A1 (en) 1992-05-26 1993-12-09 Smithkline Beecham Corporation Compositions useful in diagnosis and prophylaxis of lyme disease
US6303129B1 (en) 1992-07-28 2001-10-16 Rx Technologies Production of borrelia burgdorferi vaccine, product produced thereby and method of use
US5686078A (en) 1992-09-14 1997-11-11 Connaught Laboratories, Inc. Primary and secondary immunization with different physio-chemical forms of antigen
WO1994006463A1 (en) 1992-09-14 1994-03-31 Pfizer Inc Immortalized cells and uses therefor
AU689466B2 (en) 1993-02-26 1998-04-02 Cambridge Biotech Corporation Methods of inducing immunity to lyme disease and a colorimetric assay for borreliacidal activity of antisera
DE69408135T2 (de) 1993-04-29 1998-06-10 Immuno Ag Ospc-antigen-impfstoffe immunogene zusammensetzung zur vorbeugung und behandlung von lyme-krankheit und rekombinante verfahren zur herstellung von derartige antigene
US5656451A (en) 1993-07-30 1997-08-12 Yale University OspE, OspF, and S1 polypeptides in borrelia burgdorferi
EP0757556B1 (en) * 1994-04-11 2006-06-14 Wyeth Holdings Corporation Borrelia burgdorferi bacterin
US6143788A (en) 1995-03-10 2000-11-07 G.D. Searle & Co. Bis-amino acid hydroxyethlamino sulfonamide retroviral protease inhibitors
US7339078B2 (en) 1995-03-10 2008-03-04 G.D. Searle Llc Bis-amino acid hydroxyethylamino sulfonamide retroviral protease inhibitors
EP1188766A1 (en) 1995-03-10 2002-03-20 G.D. Searle & Co. Bis-amino acid hydroxyethylamino sulfonamide retroviral protease inhibitors
US6861539B1 (en) 1995-03-10 2005-03-01 G. D. Searle & Co. Bis-amino acid hydroxyethylamino sulfonamide retroviral protease inhibitors
US6150556A (en) 1995-03-10 2000-11-21 G. D. Dearle & Co. Bis-amino acid hydroxyethylamino sulfonamide retroviral protease inhibitors
EP0880543A4 (en) 1995-10-26 2000-08-02 Rhode Island Education ANTIGENS AS VACCINE CANDIDATES FOR THE SPICK-INDUCED LYME DISEASE SPIROCHETES (BORRELIA BURGDORFERI) BY TICK VECTORS (IXODES SCAPULARIS)
WO1997026273A1 (en) 1996-01-22 1997-07-24 The Regents Of The University Of California Borrelia burgdorferi outer membrane proteins
US6045804A (en) 1996-03-07 2000-04-04 Mayo Foundation For Medical Educational Research Method for detecting B. burgdorferi infection
US6368603B1 (en) 1997-03-05 2002-04-09 Merial Limited Lyme combination compositions and uses
GB9711990D0 (en) 1997-06-11 1997-08-06 Smithkline Beecham Biolog Vaccine
WO1999000413A1 (en) 1997-06-30 1999-01-07 The Administrators Of The Tulane Educational Fund Surface antigens and proteins useful in compositions for the diagnosis and prevention of lyme disease
DE19740735A1 (de) 1997-09-16 1999-03-18 Max Planck Gesellschaft Arzneimittel zur Therapie einer manifesten Lyme-Borreliose
PT1042001E (pt) 1997-12-16 2002-09-30 Chiron Corp Uso de microparticulas combinadas com emulsoes submicronicas oleo-em-agua
US7393630B2 (en) 1997-12-16 2008-07-01 Novartis Vaccines And Diagnostics, Inc. Use of microparticles combined with submicron oil-in-water emulsions
US20010036658A1 (en) 1997-12-19 2001-11-01 Phillips Steven E. Culture media for growing spirochetes
GB9811219D0 (en) 1998-05-26 1998-07-22 Smithkline Beecham Biolog Novel process
DK1100922T3 (da) * 1998-07-31 2008-06-16 Gundersen Lutheran Medical Fou Anvendelser af én eller flere borreliacide epitoper på ydermembranprotein C fra Borrelia burgdorferi (OspC) som vaccine
US6592875B1 (en) 1999-06-21 2003-07-15 Milkhaus Laboratory, Inc. Method for treatment of lyme disease
US6517838B1 (en) 2000-06-16 2003-02-11 The Texas A&M University System Decorin binding protein essential peptides and methods of use
US20040197339A1 (en) 2003-01-29 2004-10-07 Brown Paul R. Vaccine for Lyme disease
US20050089533A1 (en) * 2003-01-29 2005-04-28 Joseph Frantz Canine vaccines against Bordetella bronchiseptica
GB0315323D0 (en) * 2003-07-01 2003-08-06 Royal Veterinary College Vaccine composition
US20050202046A1 (en) 2004-03-11 2005-09-15 Wyeth Canine vaccine for protection against ehrlichiosis
US7985209B2 (en) 2005-12-15 2011-07-26 Kimberly-Clark Worldwide, Inc. Wound or surgical dressing
US20090324638A1 (en) 2006-06-12 2009-12-31 Biopeptides Corp. Live bacterial vaccine
DE102006045252B4 (de) 2006-09-26 2012-12-27 Euroimmun Medizinische Labordiagnostika Ag Protein-freies Medium für die Kultivierung von Borrelien und dessen Benutzung
CA2664619C (en) 2006-10-12 2012-12-11 Glaxosmithkline Biologicals S.A. Immunogenic compositions comprising an oil-in-water emulsion adjuvant containing a reduced amount of squalene, tocol and an emulsifying agent
MX2009004866A (es) * 2006-11-03 2009-05-19 Schering Plough Ltd Vacuna para enfermedad de lyme canina.

Also Published As

Publication number Publication date
CA2668405A1 (en) 2008-05-15
CA2668405C (en) 2015-05-05
IL198485A0 (en) 2011-08-01
NZ576564A (en) 2012-03-30
US20120141530A1 (en) 2012-06-07
JP2017019873A (ja) 2017-01-26
EP2077856A2 (en) 2009-07-15
CO6190537A2 (es) 2010-08-19
ZA200903378B (en) 2010-03-31
BRPI0719360A2 (pt) 2014-02-04
JP5177824B2 (ja) 2013-04-10
AU2007318026B2 (en) 2013-04-18
US8137678B2 (en) 2012-03-20
CN101573135A (zh) 2009-11-04
JP2012211205A (ja) 2012-11-01
WO2008057396A3 (en) 2008-10-16
KR101192127B1 (ko) 2012-10-17
JP6073594B2 (ja) 2017-02-01
WO2008057396A2 (en) 2008-05-15
EP2077856B1 (en) 2015-08-12
MX2009004866A (es) 2009-05-19
KR20090077018A (ko) 2009-07-13
RU2460538C2 (ru) 2012-09-10
JP2010509217A (ja) 2010-03-25
SG176451A1 (en) 2011-12-29
US20080181916A1 (en) 2008-07-31
RU2009120894A (ru) 2010-12-10
AU2007318026A1 (en) 2008-05-15
BRPI0719360B1 (pt) 2016-09-06
US8414901B2 (en) 2013-04-09
CN101573135B (zh) 2013-06-12
WO2008057396A8 (en) 2009-07-23

Similar Documents

Publication Publication Date Title
MX2009004866A (es) Vacuna para enfermedad de lyme canina.
HUS2500037I1 (hu) Javított protofibril szelektív antitestek és alkalmazásuk
GB2443287B (en) Methods, compositions and formulations for the treatment of thyroid eye disease
AU2013201592A1 (en) Improved vaccines and methods for using the same
MX2009013628A (es) Vacunas que contienen variantes geneticas de parvovirus canino.
MX2009008430A (es) Anticuerpos anti-robo4 y sus usos.
PL1971366T3 (pl) Ludzkie przeciwciała skierowane przeciw IL-23, kompozycje, sposoby i zastosowanie
ZA200901132B (en) Human GLP-1 mimetibodies, compositions, methods and uses
IL226164A0 (en) Surgical suturing device, method and tools used with it
MX2009004291A (es) Metodos para asegurar extremos de hebra y los dispositivos resultantes.
MX379016B (es) Composiciones y metodos para tratar enfermedad de gaucher.
GB0504436D0 (en) Vaccine
EP2131757A4 (en) MAXILLARY BONE CUT SYSTEM, KIT, AND METHOD OF USE THEREOF
WO2011142858A3 (en) Chlorotoxin variants, conjugates, and methods for their use
IL193392A0 (en) Influenza antibodies, compositions, and related methods
IL198400A0 (en) Surgical cutting devices and methods
EP2046936A4 (en) BIOCIDAL COMPOSITIONS AND METHODS
MY151051A (en) Vaccination against dengue virus infection
ZA200807945B (en) Skin lightening agents, compositions and methods
ZA200807944B (en) Skin lightening agents, compositions and methods
PH12013502194A1 (en) Antibodies to egfl7 and methods for their use
GB0616111D0 (en) Agents, methods and uses
IL186851A0 (en) Styrylsulfonamides, their manufacture and use as pharmaceutical agents
GB0519871D0 (en) Immunogenic agents
BRPI0919168A2 (pt) pestivírus mutante, e, vacina.